https://www.thecardiologyadvisor.com/home/topics/metabolic/sglt2-inhibitors-improve-cv-renal-and-mortality-outcomes-in-ckd-and-hf/
0
0
SGLT2 Inhibitors Improve CV, Renal, and Mortality Outcomes in CKD and HF - The Cardiology Advisor
1/6/23 at 1:12pm
Organization
Thecardiologyadvisor.com
Authors
Jessica Nye PhD
36 words
0
Comments
A study sought to assess outcomes in patients with CKD and/or heart failure without diabetes being treated with SGLT2 inhibitors.
You are the first to view
Create an account or login to join the discussion